The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
Open accessAbstract
Purpose Bone complications of metastatic disease, including skeletal-related events (SREs), impair patients' functioning and quality of life. In a randomized, phase 3 trial of 1,776 patients with metastases from solid tumors (except breast or prostate) or multiple myeloma, denosumab was non-inferior to zoledronic acid (ZA) in delaying or preventing SREs. This ad hoc analysis reports outcomes in the subgroup of 1,597 patients with solid tumors, excluding patients with multiple myeloma.Methods Patients received monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg, adjusted for creatinine clearance, with calcium and vitamin D supplementation recommended. Endpoints included times to first on-study SRE, first-and-subsequent SREs, and pain worsening.Results Denosumab significantly delayed time to first on-study SRE compared with ZA (HR, 0.81; 95 % CI, 0.68-0.96) and time to first-and-subsequent SREs (RR, 0.85; 95 % CI, 0.72-1.00). Denosumab also significantly delayed time to development of moderate or severe pain (HR, 0.81; 95 % CI, 0.66-1.00), pain worsening (HR, 0.83; 95 % CI, 0.71-0.97), and worsening pain interference in patients with no/mild baseline pain (HR, 0.77; 95 % CI, 0.61-0.96). Adverse event rates were 96 % in both groups. Grade 3 or 4 hypocalcemia, mostly without clinical sequelae, was more frequent in denosumab-treated patients (denosumab 4 %, ZA 2 %). Osteonecrosis of the jaw occurred infrequently (denosumab 0.8 %, ZA 1.1 %).Conclusions Denosumab was more effective in delaying or preventing SREs in patients with bone metastases from solid tumors and also prevented pain progression compared to ZA in this ad hoc analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study of denosumab versus zoledronic acid in patients with advanced cancers, the time extent to which pain interfered with daily life (used as surrogate for QoL) was longer in patients treated with denosumab and with no pain or mild pain interference at baseline [163].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,752
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,489
Fizazi, K. S., Carducci, M. A., Smith, M. R., Damião, R., Brown, J. E., Karsh, L. I., Milecki, P., Shore, N. D., Rader, M. E., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,974
Stopeck, A., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K. S., Boer, R. H. D., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,617
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausová, J., Scagliotti, G. V., Sleeboom, H. P., Spencer, A. G., Vadhan‐Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,271
Portenoy, R. K., & Lesage, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01310-0 · Cited by 1,013
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 872
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Fred Saad, C., Lipton, A., Cook, R. J., Chen, Y., Smith, M. R., & Coleman, R. E. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 664
Lipton, A., Fizazi, K. S., Stopeck, A., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 592
Cited by
Sorted by citations
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
“In the study of denosumab versus zoledronic acid in patients with advanced cancers, the time extent to which pain interfered with daily life (used as surrogate for QoL) was longer in patients treated with denosumab and with no pain or mild pain interference at baseline [163].”
BackgroundPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“In the study of denosumab versus zoledronic acid in patients with advanced cancers, the time extent to which pain interfered with daily life (used as surrogate for QoL) was longer in patients treated with denosumab and with no pain or mild pain interference at baseline [319].”
BackgroundBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Ruggiero, S. L., Dodson, T. B., Aghaloo, T. L., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,209
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S. B., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 575
Metadata
- Authors
- Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., Jun, S., Dansey, R., & Yeh, H.
- Affiliations
- Pennsylvania Hospital (US)
- McGill University Health Centre (CA)
- University of Sheffield (GB)
- University of Turin (IT)
- Amgen (United States) (US)
- Corresponding author
- Henry, David
- Venue
- Supportive Care in Cancer
- Published
- 2013-10-26
- Volume
- 22
- Issue
- 3
- Pages
- 679-687
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2066699153
- Cited by
- 183
- References
- 23
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 11 · 2020: 21 · 2019: 17 · 2018: 14 · 2017: 10 · 2016: 16 · 2015: 21 · 2014: 16 · 2013: 1
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- denosumab, zoledronic acid, skeletal-related events, bone metastasis, solid tumors, bone pain, hypocalcemia, osteonecrosis of the jaw, bisphosphonates, non-inferiority, metastatic cancer
- MeSH terms
- Denosumab, Zoledronic Acid, Adolescent, Adult, Aged, Aged, 80 and over, Bone Neoplasms, Bone Resorption, Diphosphonates, Double-Blind Method, Female, Humans, Imidazoles, Male, Middle Aged, Multiple Myeloma, Neoplasms, Pain, Treatment Outcome, Disease Progression, Bone Density Conservation Agents, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
